What have clinical & immune analyses of MSCs revealed and what does it mean for resistant psoriasis?

During the 1st International Societies for Investigative Dermatology (ISID) meeting, the Psoriasis and Psoriatic Arthritis Hub was pleased to speak to Su Mar Lwin, St John’s Institute of Dermatology, London, UK and Christopher Griffiths, University of Manchester, Manchester, UK and King’s College London, London, UK. We asked, What have clinical & immune analyses of MSCs revealed and what does it mean for resistant psoriasis?

In this video interview, Su Mar Lwin outlines the indications of stem cell therapy in resistant psoriasis, including its mode of action and the characteristics which make MSCs useful in this patient group.

Christopher Griffiths goes on to discuss two real life cases of patients who were treated with MSCs. The speakers outline the impacts of treatment in each case, highlighting patient-reported symptom outcomes and psoriasis area and severity index status. The immune cell response following MSC treatment is also discussed, with both speakers providing their insight into the application of MSCs and which patients may benefit most from infusion.